Literature DB >> 7387629

Purification of Torpedo californica post-synaptic membranes and fractionation of their constituent proteins.

J Elliott, S G Blanchard, W Wu, J Miller, C D Strader, P Hartig, H P Moore, J Racs, M A Raftery.   

Abstract

A rapid methof for preparation of membrane fractions highly enriched in nicotinic acetylcholine receptor from Torpedo californica electroplax is described. The major step in this purification involves sucrose-density-gradient centrifugation in a reorienting rotor. Further purification of these membranes can be achieved by selective extraction of proteins by use of alkaline pH or by treatment with solutions of lithium di-idosalicylate. The alkali-treated membranes retain functional characteristics of the untreated membranes and in addition contain essentially only the four polypeptides (mol.wts. 40000, 50000, 60000 and 65000) characteristic of the receptor purified by affinity chromatography. Dissolution of the purified membranes or of the alkali-treated purified membranes in sodium cholate solution followed by sucrose-density-gradient centrifugation in the same detergent solution yields solubilized receptor preparations comparable with the most highly purified protein obtained by affinity-chromatographic procedures.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387629      PMCID: PMC1161444          DOI: 10.1042/bj1850667

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Affinity-labeling of purified acetylcholine receptor from Torpedo californica.

Authors:  C L Weill; M G McNamee; A Karlin
Journal:  Biochem Biophys Res Commun       Date:  1974-12-11       Impact factor: 3.575

2.  Presence of a lattice structure in membrane fragments rich in nicotinic receptor protein from the electric organ of Torpedo marmorata.

Authors:  J Cartaud; E L Benedetti; J B Cohen; J C Meunier; J P Changeux
Journal:  FEBS Lett       Date:  1973-06-15       Impact factor: 4.124

3.  Ultrastructure of isolated membranes of Torpedo electric tissue.

Authors:  E Nickel; L T Potter
Journal:  Brain Res       Date:  1973-07-27       Impact factor: 3.252

4.  Fractionation and partial characterization of membrane particles from Torpedo californica electroplax.

Authors:  J R Duguid; M A Raftery
Journal:  Biochemistry       Date:  1973-09-11       Impact factor: 3.162

5.  Selective solubilization of proteins from red blood cell membranes by protein perturbants.

Authors:  T L Steck; J Yu
Journal:  J Supramol Struct       Date:  1973

6.  Specificity of -bungarotoxin binding to Torpedo californica electroplax.

Authors:  M A Raftery; J Schmidt; D G Clark
Journal:  Arch Biochem Biophys       Date:  1972-10       Impact factor: 4.013

7.  Purification from Torpedo marmorata electric tissue of membrane fragments particularly rich in cholinergic receptor protein.

Authors:  J B Cohen; M Weber; M Huchet; J P Changeux
Journal:  FEBS Lett       Date:  1972-10-01       Impact factor: 4.124

8.  A simple assay for the study of solubilized acetylcholine receptors.

Authors:  J Schmidt; M A Raftery
Journal:  Anal Biochem       Date:  1973-04       Impact factor: 3.365

9.  Use of affinity chromatography for acetylcholine receptor purification.

Authors:  J Schmidt; M A Raftery
Journal:  Biochem Biophys Res Commun       Date:  1972-10-17       Impact factor: 3.575

10.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

View more
  51 in total

Review 1.  Nicotinic receptor-associated 43K protein and progressive stabilization of the postsynaptic membrane.

Authors:  J A Hill
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

2.  Extraction of peripheral proteins is accompanied by selective depletion of certain glycerophospholipid classes and changes in the phosphorylation pattern of acetylcholine-receptor-rich-membrane proteins.

Authors:  I C Bonini de Romanelli; A M Roccamo de Fernández; F J Barrantes
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

3.  A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.

Authors:  Badiga Venkata Aruna; Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

4.  Lipid-protein interactions in membranes containing the acetylcholine receptor.

Authors:  M G McNamee; J F Ellena; A W Dalziel
Journal:  Biophys J       Date:  1982-01       Impact factor: 4.033

Review 5.  End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease.

Authors:  Steven M Sine
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

6.  Nicotinic acetylcholine receptor contains multiple binding sites: evidence from binding of alpha-dendrotoxin.

Authors:  B M Conti-Tronconi; M A Raftery
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

7.  The subsynaptic 43-kDa protein is concentrated at developing nerve-muscle synapses in vitro.

Authors:  S J Burden
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Creatine kinase activity in the Torpedo electrocyte and in the nonreceptor, peripheral v proteins from acetylcholine receptor-rich membranes.

Authors:  F J Barrantes; G Mieskes; T Wallimann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.

Authors:  Hava Ben-David; Amir Sharabi; Molly Dayan; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

10.  Molecular environment of the phencyclidine binding site in the nicotinic acetylcholine receptor membrane.

Authors:  A L Palma; H H Wang
Journal:  J Membr Biol       Date:  1991-06       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.